BRPI0618385A2 - uso de uma combinação de testosterona ou um análogo da mesma com tadalafil, kit de partes, e, uso de uma combinação de testosterona ou um análogo da mesma com um composto - Google Patents

uso de uma combinação de testosterona ou um análogo da mesma com tadalafil, kit de partes, e, uso de uma combinação de testosterona ou um análogo da mesma com um composto Download PDF

Info

Publication number
BRPI0618385A2
BRPI0618385A2 BRPI0618385-9A BRPI0618385A BRPI0618385A2 BR PI0618385 A2 BRPI0618385 A2 BR PI0618385A2 BR PI0618385 A BRPI0618385 A BR PI0618385A BR PI0618385 A2 BRPI0618385 A2 BR PI0618385A2
Authority
BR
Brazil
Prior art keywords
analog
testosterone
combination
tadalafil
female sexual
Prior art date
Application number
BRPI0618385-9A
Other languages
English (en)
Inventor
Jan Johan Adriaan Tuiten
Johannes Martinus Maria Bloemers
Original Assignee
Emotional Brain Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emotional Brain Bv filed Critical Emotional Brain Bv
Publication of BRPI0618385A2 publication Critical patent/BRPI0618385A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE UMA COMBINAçãO DE TESTOSTERONA OU UM ANáLOGO DA MESMA COM TADALAFIL, KIT DE PARTES, E, USO DE UMA COMBINAçãO DE TESTOSTERONA OU UM ANALOGO DA MESMA COM UM COMPOSTO. A invenção diz respeito ao campo da disfunção sexual feminina. Especificamente diz respeito à influência da combinação da testosterona ou um análogo da mesma, com o tadalafil, sobre a saúde sexual em indivíduos femininos com Disfunção Sexual Feminina (tal como o Distúrbio de Excitação Sexual Feminina (FSAD) ou Distúrbio do Desejo Sexual Feminino (FSDD). Diz respeito ainda à influência da combinação da testosterona, ou de um análogo do mesmo, com um composto capaz de, pelo menos em parte, inibir a contração dos músculos lisos, por exemplo um composto capaz de, pelo menos em parte, inibir a tonalidade adrenérgica. A invenção ainda descreve outras terapias combinatórias no tratamento da Disfunção Sexual Feminina.
BRPI0618385-9A 2005-11-11 2006-11-10 uso de uma combinação de testosterona ou um análogo da mesma com tadalafil, kit de partes, e, uso de uma combinação de testosterona ou um análogo da mesma com um composto BRPI0618385A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05077577A EP1790343A1 (en) 2005-11-11 2005-11-11 Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
PCT/NL2006/000542 WO2007055563A2 (en) 2005-11-11 2006-11-10 Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
BRPI0618385A2 true BRPI0618385A2 (pt) 2011-08-30

Family

ID=36118697

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618385-9A BRPI0618385A2 (pt) 2005-11-11 2006-11-10 uso de uma combinação de testosterona ou um análogo da mesma com tadalafil, kit de partes, e, uso de uma combinação de testosterona ou um análogo da mesma com um composto

Country Status (27)

Country Link
US (3) US9333203B2 (pt)
EP (2) EP1790343A1 (pt)
JP (2) JP2009515875A (pt)
KR (5) KR20170029011A (pt)
CN (2) CN103083325B (pt)
AU (1) AU2006312373B2 (pt)
BR (1) BRPI0618385A2 (pt)
CA (1) CA2629364C (pt)
CY (1) CY1122051T1 (pt)
DK (1) DK1965802T3 (pt)
EA (2) EA034539B1 (pt)
ES (1) ES2744206T3 (pt)
HK (1) HK1128226A1 (pt)
HR (1) HRP20191544T1 (pt)
HU (1) HUE045846T2 (pt)
IL (1) IL191280A (pt)
LT (1) LT1965802T (pt)
ME (1) ME03499B (pt)
NO (3) NO342986B1 (pt)
NZ (1) NZ567963A (pt)
PL (1) PL1965802T3 (pt)
PT (1) PT1965802T (pt)
RS (1) RS59268B1 (pt)
SI (1) SI1965802T1 (pt)
UA (2) UA97101C2 (pt)
WO (1) WO2007055563A2 (pt)
ZA (2) ZA200804443B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005239962B2 (en) 2004-05-11 2011-07-07 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
ES2825799T3 (es) * 2011-05-13 2021-05-17 Acerus Biopharma Inc Formulaciones en gel de testosterona intranasal de concentración de dosis más baja y uso de las mismas para tratar anorgasmia o trastorno del deseo sexual hipoactivo
MX2013013369A (es) * 2011-05-15 2014-10-17 Trimel Biopharma Srl Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino.
FR2999086B1 (fr) * 2012-12-10 2015-04-10 Ethypharm Sa Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
NZ731850A (en) 2014-11-14 2023-06-30 Follea Int System and method for preventing alopecia
WO2016201286A1 (en) * 2015-06-11 2016-12-15 Applied Biology, Inc. Treatment of sexual dysfunction
US11717495B2 (en) * 2020-03-16 2023-08-08 Vella Bioscience, Inc. Use of cannabinoids in treating anti-depressant-induced female sexual dysfunction

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
NZ209876A (en) * 1983-10-17 1988-03-30 Duphar Int Res Piperazines and pharmaceutical compositions
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) * 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
RU2152787C2 (ru) 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
DE69420746T2 (de) 1994-06-02 2000-06-29 Dan Riga Arzneimittel gegen stress, beeinträchtigung und altwerden und verfahren zu ihrer herstellung
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
EP0758653A4 (en) 1995-03-01 1998-06-10 Kyowa Hakko Kogyo Kk IMIDAZOQUINAZOLINE DERIVATIVES
JPH10505611A (ja) 1995-03-14 1998-06-02 ヴィヴァス・インコーポレーテッド 勃起機能不全を予防するための方法およびキット
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
WO1996036339A2 (en) 1995-05-15 1996-11-21 Beth Israel Hospital Use of dihydrotestosterone compounds for treating male sexual dysfunction
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
JP2000511046A (ja) * 1996-05-17 2000-08-29 アンドルシェルシュ・インコーポレイテッド 単離されたウリジンジホスホ―グルクロノシルトランスフェラーゼの性質とその使用
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
CA2294480C (en) * 1997-06-23 2008-05-20 Queen's University At Kingston Microdose therapy of female sexual dysfunction by no, co, and their donors
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
JP2001520999A (ja) 1997-10-28 2001-11-06 アシビ， エルエルシー 女性の性的機能不全の処置
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6246436B1 (en) * 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
AU3879299A (en) * 1998-05-07 1999-11-23 Axys Pharmaceuticals, Inc. Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6448003B1 (en) * 1998-06-10 2002-09-10 Dna Sciences Laboratories, Inc. Genotyping the human phenol sulfotransferbase 2 gene STP2
US6407117B1 (en) * 1998-06-18 2002-06-18 The George Washington University Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
US6319678B1 (en) * 1998-06-26 2001-11-20 Panvera Corporation Process for glucuronidation screening
US6586175B1 (en) * 1998-07-28 2003-07-01 Dna Sciences Laboratories, Inc. Genotyping the human UDP-glucuronosyltransferase 2B7 (UGT2B7) gene
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
WO2000066114A1 (en) 1999-04-30 2000-11-09 Lilly Icos Llc Treatment of female arousal disorder
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US6632419B2 (en) * 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
NZ516223A (en) 1999-06-17 2003-08-29 Pharmacia Ab Use of growth hormone (hGH) for the treatment of sexual dysfunction
RU2180591C2 (ru) 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
DE10016548A1 (de) * 2000-04-03 2001-10-11 Bayer Ag Polyurethan-Dispersionen
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
US20040076968A1 (en) * 2000-07-14 2004-04-22 Gonzalo Acuna Method for detecting pre-disposition to hepatotoxicity
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
DE60141587D1 (de) 2000-08-30 2010-04-29 Besins Int Lab Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
KR100833469B1 (ko) 2000-09-29 2008-05-29 솔베이 파마슈티칼스 비. 브이 이온 농도에 비의존적인 지속 방출성 약제학적 제형
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
AU2002221112A1 (en) * 2000-12-12 2002-06-24 Nagoya Industrial Science Research Institute Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
DE10100238A1 (de) * 2001-01-05 2002-08-22 Hannover Med Hochschule Verfahren zur Vorhersage des Gefährdungspotentials für Karzinomerkrankungen und entzündliche Darmerkrankungen und zugehörige Tests
US20030099960A1 (en) * 2001-01-26 2003-05-29 The University Of Chicago Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
EP1383502A4 (en) 2001-03-06 2007-07-25 Strakan Int Ltd COMPOUNDS AND METHOD FOR TREATING UROGENITAL DISORDER
EP1373192A1 (en) * 2001-03-28 2004-01-02 Pfizer Limited N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
EP1653966A1 (en) * 2003-07-16 2006-05-10 Pfizer Limited Treatment of sexual dysfunction
DE60303854T2 (de) * 2003-11-11 2006-08-10 Mattern, Udo Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen
WO2005094827A1 (en) 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
BRPI0510074A (pt) 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
AU2005239962B2 (en) * 2004-05-11 2011-07-07 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US20070154533A1 (en) * 2005-04-13 2007-07-05 Dudley Robert E Method of increasing testosterone and related steriod concentrations in women
WO2006127057A1 (en) 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
WO2006125642A1 (en) * 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
WO2007054791A2 (en) 2005-11-08 2007-05-18 L'oréal Androgen glucuronides as markers of androgenic activity
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
HUE027647T2 (en) 2007-11-28 2016-10-28 Ucb Pharma Gmbh Polymorphic form of Rotigotine

Also Published As

Publication number Publication date
SI1965802T1 (sl) 2019-10-30
EA201400423A1 (ru) 2015-01-30
ZA200903527B (en) 2010-04-28
JP5959483B2 (ja) 2016-08-02
EA034539B1 (ru) 2020-02-18
ES2744206T3 (es) 2020-02-24
KR20170029011A (ko) 2017-03-14
CY1122051T1 (el) 2020-10-14
KR20080084943A (ko) 2008-09-22
AU2006312373B2 (en) 2013-01-10
JP2013241463A (ja) 2013-12-05
US20170042911A1 (en) 2017-02-16
CN101346143A (zh) 2009-01-14
CN103083325A (zh) 2013-05-08
NO20170799A1 (no) 2008-07-31
RS59268B1 (sr) 2019-10-31
KR20150110829A (ko) 2015-10-02
HRP20191544T1 (hr) 2019-11-29
PL1965802T3 (pl) 2020-01-31
CA2629364C (en) 2013-07-09
PT1965802T (pt) 2019-09-19
IL191280A0 (en) 2009-08-03
US9333203B2 (en) 2016-05-10
CA2629364A1 (en) 2007-05-18
US20160213683A1 (en) 2016-07-28
EA021540B1 (ru) 2015-07-30
JP2009515875A (ja) 2009-04-16
HK1128226A1 (en) 2009-10-23
KR20160128466A (ko) 2016-11-07
CN103083325B (zh) 2017-08-11
NO343941B1 (no) 2019-07-22
EP1965802B1 (en) 2019-06-05
EP1965802A2 (en) 2008-09-10
DK1965802T3 (da) 2019-09-16
HUE045846T2 (hu) 2020-01-28
EA200801310A1 (ru) 2009-04-28
EP1790343A1 (en) 2007-05-30
NZ567963A (en) 2012-04-27
ZA200804443B (en) 2009-10-28
LT1965802T (lt) 2019-09-10
WO2007055563A3 (en) 2007-09-07
CN101346143B (zh) 2013-01-30
US9737548B2 (en) 2017-08-22
AU2006312373A1 (en) 2007-05-18
UA97101C2 (uk) 2012-01-10
NO20082703L (no) 2008-07-31
NO20170800A1 (no) 2008-07-31
IL191280A (en) 2016-02-29
UA112406C2 (uk) 2016-09-12
NO342986B1 (no) 2018-09-17
ME03499B (me) 2020-04-20
KR20140070656A (ko) 2014-06-10
WO2007055563A2 (en) 2007-05-18
US20090306026A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
BRPI0618385A2 (pt) uso de uma combinação de testosterona ou um análogo da mesma com tadalafil, kit de partes, e, uso de uma combinação de testosterona ou um análogo da mesma com um composto
BRPI0510627A (pt) combinações que compreendem um agonista do receptor s1p e um inibidor da jak3 quinase
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
BRPI0618473A2 (pt) combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
GT200600148A (es) Metodos para el tratamiento y la prevencion de fibrosis
EA200901078A1 (ru) Конъюгаты синтетических агонистов tlr и их применение
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
MX2009009207A (es) Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.
HN2005035605A (es) Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
EA201100544A1 (ru) Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
CL2008000795A1 (es) Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil)piperazina para el tratamiento del dolor o de los sintomas residuales de la depresion; y dicho compuesto.
BRPI0515319A (pt) análogos de quinolona
MXPA05009246A (es) Combinaciones antineoplasicas.
EA201001322A1 (ru) Вакцины против хламидиоза
BRPI0616962B8 (pt) uso de lactobacillus para o tratamento de doenças autoimunes
BRPI0512622A (pt) uso de compostos de peptìdeos para tratamento de tremor e outras sìndromes de tremor
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
ECSP077426A (es) USO DE UN INHIBIDOR DE mTOR EN EL TRATAMIENTO DE LEIOMIOMA UTERINO
SG161281A1 (en) Hgf beta chain variants
TN2010000155A1 (en) Organic compounds
EA201100297A1 (ru) Биотесты на белок polyq
CY1110182T1 (el) Ιδεβενονη για τη θεραπεια των μυϊκων δυστροφιων

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EB IP LYBRIDOS B.V. (NL)

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: EB IP LYBRIDO B.V. (NL)

Free format text: RETIFICACAO DO DESPACHO "(25.1) TRANSFERENCIA DE TITULARIDADE" PUBLICADO NA RPI NO 2392, DE 08/11/2016, QUANTO AO ITEM "(71) - DEPOSITANTE". ONDE SE LE: "EB IP LYBRIDOS B.V." LEIA-SE: "EB IP LYBRIDO B.V."

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL